Argus raises Cardinal Health stock price target on strong earnings
Argus raised its price target for Cardinal Health (CAH) to $309 from $264, citing strong Q1 2027 results. The company reported 5% revenue growth and 28% adjusted EPS growth to $3.26, exceeding estimates. Cardinal Health also raised its fiscal 2027 adjusted EPS guidance to $12.80-$13.00. The stock is near its 52-week high, up 53% in six months, and is considered undervalued by InvestingPro.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift suggest stronger cash flow, supporting dividend sustainability and possible share buybacks.
Market read
The report provides fresh, material data that can move the stock and influences sector sentiment.
What to watch
Potential headwinds from drug pricing pressures and supply‑chain constraints could temper upside.
Background
Cardinal Health is a major distributor of pharmaceuticals and medical products in the United States.
Ticker impact
Cardinal Health reported Q1 FY2027 results beating estimates and raised FY2027 EPS guidance to $12.80‑$13.00, prompting analyst price‑target hikes.
upward pressure as investors price in higher earnings outlook and raised price targets
Earnings beat, 5% revenue growth, 28% EPS growth and guidance lift are material new information for a large‑cap health‑services stock.
Market effects
Boosts outlook for pharmaceutical distribution and specialty services sector.
Positive for U.S. healthcare services equities.
Limited to U.S. market; no direct global ripple.
Counterpoint
If the guidance raise is already priced in, the stock may face short‑term profit‑taking.
Key entities
- companyCardinal Health
U.S. healthcare services and distribution firm.
- analystArgus Research
Raised price target to $309 on the earnings beat.





